TG Therapeutics, Inc.

As of October 24, 2025, TG Therapeutics, Inc. shows a mildly bearish trend overall, with mixed signals from various indicators, including a mildly bullish weekly MACD and a bearish weekly Bollinger Bands.

As of October 24, 2025, TG Therapeutics, Inc. shows a mildly bearish trend with mixed signals from technical indicators, underperforming the S&P 500 recently but significantly outperforming it over the past year.

As of October 24, 2025, TG Therapeutics, Inc. is in a mildly bearish trend, underperforming the S&P 500 in the short term but outperforming it over the past year.

As of October 3, 2025, TG Therapeutics, Inc. shows a neutral trend with mixed indicators, including mildly bullish weekly MACD and Bollinger Bands, but a mildly bearish daily moving average and KST, indicating a lack of strong momentum in either direction.

As of October 3, 2025, TG Therapeutics, Inc. shows a neutral trend with mixed technical indicators, including mildly bullish MACD on the weekly chart and bearish KST on both weekly and monthly charts, while outperforming the S&P 500 with a 1-year return of 65.41%.

As of August 21, 2025, TG Therapeutics, Inc. has shifted to a mildly bearish trend, indicated by a bearish MACD and mixed signals from KST and Bollinger Bands, despite outperforming the S&P 500 over the past year with a 29.15% return.

As of June 30, 2025, TG Therapeutics, Inc. is considered very expensive with a high P/E ratio of 158 and other valuation metrics significantly exceeding its peers, despite impressive 3-year returns of 380.27%.

As of March 3, 2025, TG Therapeutics, Inc. is considered overvalued with a P/E ratio of 158, significantly higher than its peers, indicating a shift from risky to expensive valuation despite its strong past performance.

As of June 10, 2025, the technical trend is mildly bullish, supported by positive daily moving averages and a bullish RSI, despite some caution from weekly indicators.

As of March 2022, TG Therapeutics, Inc.'s management team includes Mr. Michael Weiss as Executive Chairman, President, and CEO, along with independent directors Mr. Laurence Charney, Dr. Yann Echelard, Mr. Kenneth Hoberman, Mr. Daniel Hume, and Dr. William Kennedy.

TG Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for B-cell malignancies and autoimmune diseases. As of March 2025, it reported net sales of $121 million and a market cap of approximately $5.56 billion.

As of Jun 18, TG Therapeutics, Inc. has a market capitalization of $5.56 billion, with recent net sales of $386.40 million and a net profit of $39.15 million. The company reported shareholder's funds of $222.36 million and total assets of $577.69 million as of Dec 24.